August 30, 2016: In late 2015, Charbel Moussa, a researcher at UCMC, announced the results of a promising Phase I clinical trial of cancer drug.
August 30, 2016: CRO AMRI, headquartered in Albany, NY, announced that it will be restructuring specific operations in the U.S. and Europe. An unspecified number of jobs will be cut as a result. The restructuring is the direct result of the recently closed acquisition of Euticals.
August 30, 2016: Biotech companies are generally known for cutting-edge technology, incredibly high burn rates, long timelines, and volatile stocks. They are very high-risk-high-reward stock investments.
August 30, 2016: Crown Bioscience has made several changes to its leadership team, including the naming of a new CEO. This morning Crown announced that it had tapped its president, Jean Pierre Wery, as the company’s new CEO.